Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Abdullah A. Alahmed"'
Autor:
Osamah M. Alfayez, Mashael AlFaifi, Omar S. Alkhezi, Abdullah A. Alahmed, Abdullah A. Alalwan
Publikováno v:
Saudi Pharmaceutical Journal, Vol 31, Iss 12, Pp 101842- (2023)
Background: The aim of this study is to identify potential barriers to conducting and publishing pharmacy residency research. Methods: A cross-sectional study surveyed pharmacy residents in Saudi Arabia from August to September 2020. The online surve
Externí odkaz:
https://doaj.org/article/e2d94b28c9de4b1ea533f6bd87830fcf
Autor:
Abdullah A. Alahmed, Omar S. Alkhezi, Osamah M. Alfayez, Mohammed Aseeri, Ahmad J. Mahrous, Abdulaziz M. Alhossan, John Fanikos, Abdullah Alalwan
Publikováno v:
Saudi Pharmaceutical Journal, Vol 30, Iss 1, Pp 66-71 (2022)
Objective: Residency positions are highly competitive. Pharmacy students who are familiar with the ideal qualities of residency candidates and the expectations of residency programs may be more likely to obtain one of these coveted positions. This st
Externí odkaz:
https://doaj.org/article/79bd8ca950904638bc44643107448a40
Autor:
Omar S. Alkhezi, Abdullah A. Alahmed, Osamah M. Alfayez, Osama A. Alzuman, Abdulaali R. Almutairi, Omar A. Almohammed
Publikováno v:
Obesity reviews : an official journal of the International Association for the Study of ObesityREFERENCES.
Tirzepatide is a new glucagon-like peptide-1 receptor agonist (GLP-1RA) that has shown promising results for weight loss. A Bayesian network meta-analysis was conducted to compare the efficacy and safety of GLP-1RAs for obesity management. Embase and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8143d77542e671fc569c7e9937fae10b
https://pubmed.ncbi.nlm.nih.gov/36579723
https://pubmed.ncbi.nlm.nih.gov/36579723
Autor:
Abdullah A. Alahmed, Julie C. Lauffenburger, Muthiah Vaduganathan, Ahmed Aldemerdash, Clara Ting, Nayyra Fatani, John Fanikos, Leo F. Buckley
Publikováno v:
American journal of cardiovascular drugs : drugs, devices, and other interventions. 22(5)
Digoxin is indicated for the management of heart failure with reduced ejection fraction and atrial fibrillation. Despite stronger guideline recommendations for other pharmacologic and device therapies, digoxin retains a role in select patients unable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b10c75c396ac1dc4dbf9827d00e843d0
https://pubmed.ncbi.nlm.nih.gov/35739347
https://pubmed.ncbi.nlm.nih.gov/35739347
Autor:
Buckley LF; Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA., Wohlford GF; Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond, VA., Ting C; Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA., Alahmed A; Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA.; Department of Pharmacy Practice, Qassim University, Buraydah, Saudi Arabia., Van Tassell BW; Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond, VA., Abbate A; Division of Cardiology, Virginia Commonwealth University, Richmond, VA., Devlin JW; School of Pharmacy, Northeastern University, Boston, MA., Libby P; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA.
Publikováno v:
Critical care explorations [Crit Care Explor] 2020 Aug 10; Vol. 2 (8), pp. e0178. Date of Electronic Publication: 2020 Aug 10 (Print Publication: 2020).